2024
Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study
Ryckman T, McQuaid C, Cohen T, Menzies N, Kendall E. Projected health and economic effects of a pan-tuberculosis treatment regimen: a modelling study. The Lancet Global Health 2024, 12: e1629-e1637. PMID: 39159654, PMCID: PMC11413512, DOI: 10.1016/s2214-109x(24)00284-5.Peer-Reviewed Original ResearchStandard of careInitial treatment attemptNewly diagnosed tuberculosis patientsTuberculosis burdenTreatment attemptDrug susceptibility testingProportion of patientsMechanisms of benefitNon-drug costsRifampicin susceptibilityTreatment discontinuationIncremental curingSusceptibility testingDrug susceptibilityRegimen developmentTreatment regimenTuberculosis patientsRegimenRegimensTuberculosis treatmentInjection regimensTuberculosis diagnosisRegimen assignmentsNon-adherenceSimulated cohort
2020
Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis
Marx FM, Cohen T, Menzies NA, Salomon JA, Theron G, Yaesoubi R. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. The Lancet Global Health 2020, 8: e1223-e1233. PMID: 32827484, PMCID: PMC7549318, DOI: 10.1016/s2214-109x(20)30227-8.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapySecondary preventive therapyHigh-incidence settingsPost-treatment followPreventive therapyTuberculosis controlTuberculosis incidenceTreatment completionTuberculosis case findingOverall disease burdenHigh tuberculosis incidenceTuberculosis-endemic settingHigh-incidence communityFirst yearHealth system costsRecurrent tuberculosisSecondary preventionAnnual followTuberculosis treatmentDisease burdenHigh riskCase findingSingle followSuburban Cape TownPreventive interventions
2018
Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study
Marx FM, Yaesoubi R, Menzies NA, Salomon JA, Bilinski A, Beyers N, Cohen T. Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. The Lancet Global Health 2018, 6: e426-e435. PMID: 29472018, PMCID: PMC5849574, DOI: 10.1016/s2214-109x(18)30022-6.Peer-Reviewed Original ResearchConceptsHigh-incidence settingsIsoniazid preventive therapyPreventive therapyTuberculosis treatmentActive casesHIV prevalenceTuberculosis controlControl interventionsIncident tuberculosis casesPrevious tuberculosis treatmentTuberculosis control interventionsTB case notificationHigh-risk groupTransmission dynamic modelTuberculosis deathsHigh tuberculosisRecurrent diseasePrevalent tuberculosisTuberculosis casesTuberculosis incidenceCase notificationTreatment outcomesTuberculosis morbidityTuberculosis epidemicAdditional interventionsThe impact of digital health technologies on tuberculosis treatment: a systematic review
Ngwatu B, Nsengiyumva N, Oxlade O, Mappin-Kasirer B, Nguyen N, Jaramillo E, Falzon D, Schwartzman K, Abubakar I, Alipanah N, Bastos M, Boccia D, Chin D, Cohen T, Davis J, Denkinger C, Falzon D, Fielding K, Fox G, Free C, Garfein R, Hayward A, Jaramillo E, Lester R, Lewis J, Mappin-Kasirer B, Marx F, Menzies D, Migliori G, Nahid P, Ngwatu B, Nsengiyumva N, Nguyen N, Oxlade O, Schwartzman K, Siddiqi K, Story A, Thomas B, Trajman A, Yassin M. The impact of digital health technologies on tuberculosis treatment: a systematic review. European Respiratory Journal 2018, 51: 1701596. PMID: 29326332, PMCID: PMC5764088, DOI: 10.1183/13993003.01596-2017.Peer-Reviewed Original ResearchConceptsVideo-observed therapyMedication monitorsStandard careObservational studyTreatment completion ratesTB treatment adherenceProbability of cureTreatment of personsPerson DOTActive tuberculosisTB careClinical outcomesTreatment adherenceTuberculosis treatmentPatient outcomesTreatment completionControl groupTreatment dosesSystematic reviewDigital health technologiesShort message serviceEffect estimatesTuberculosisDigital interventionsCare
2017
Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model
Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLOS Medicine 2017, 14: e1002202. PMID: 28045934, PMCID: PMC5207633, DOI: 10.1371/journal.pmed.1002202.Peer-Reviewed Original ResearchConceptsEase of adherenceTB mortalityTB incidenceNovel drug regimensTB regimenNovel regimenDrug regimensRegimen characteristicsTreatment durationTreatment efficacyRR-TB treatmentTB treatment efficacyRifampicin-resistant TBTB treatment durationDynamic transmission modelTB regimensNew regimensRR-TBTB treatmentMedical contraindicationsPatients' qualitySafety profileBaseline prevalenceTB epidemicTuberculosis treatment
2014
The Impact of Antiretroviral Therapy on Mortality in HIV Positive People during Tuberculosis Treatment: A Systematic Review and Meta-Analysis
Odone A, Amadasi S, White RG, Cohen T, Grant AD, Houben RM. The Impact of Antiretroviral Therapy on Mortality in HIV Positive People during Tuberculosis Treatment: A Systematic Review and Meta-Analysis. PLOS ONE 2014, 9: e112017. PMID: 25391135, PMCID: PMC4229142, DOI: 10.1371/journal.pone.0112017.Peer-Reviewed Original ResearchConceptsHIV-positive peopleAntiretroviral therapyTB treatmentTuberculosis treatmentSystematic reviewHIV-positive TB casesCoverage of ARTRisk of deathMain outcome measuresOutcomes of interestTB casesDual epidemicsTB therapyRelative riskOutcome measuresPooled estimatesStudy populationProportion of individualsFatality ratioPositive peopleMeta-AnalysisART statusClinical settingManual searchMortalityHigh risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova.
Jenkins HE, Crudu V, Soltan V, Ciobanu A, Domente L, Cohen T. High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. European Respiratory Journal 2014, 43: 1132-41. PMID: 24558181, PMCID: PMC4005038, DOI: 10.1183/09031936.00203613.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB diagnosisMDR-TB casesTB treatmentFirst-line TB drugsAmbulatory TB treatmentMDR-TB riskDrug susceptibility testingNosocomial transmissionInitial diagnosisPercentage of individualsTB drugsTuberculosis treatmentEarly treatmentHigh riskSputum specimensSurveillance databasePrevious incarcerationDrug resistanceMultidrug resistanceDiagnosisTreatmentBaseline resistanceRapid appearanceRisk
2013
Isoniazid-resistant Tuberculosis in Children
Yuen CM, Tolman AW, Cohen T, Parr JB, Keshavjee S, Becerra MC. Isoniazid-resistant Tuberculosis in Children. The Pediatric Infectious Disease Journal 2013, 32: e217-e226. PMID: 23348808, PMCID: PMC3709006, DOI: 10.1097/inf.0b013e3182865409.Peer-Reviewed Original ResearchConceptsIsoniazid-resistant tuberculosisLatent tuberculosis infectionTuberculosis diseaseTuberculosis infectionIsoniazid resistancePediatric tuberculosis patientsTreatment of childrenIsoniazid-resistant strainsReports of childrenEffective regimensTuberculosis patientsTuberculosis treatmentAppropriate treatmentInclusion criteriaMedian proportionSystematic reviewRifampin resistanceDiseaseTuberculosisRegimensChildrenTreatmentInfectionIsoniazidHigher proportion
2012
Mixed-Strain Mycobacterium tuberculosis Infections and the Implications for Tuberculosis Treatment and Control
Cohen T, van Helden PD, Wilson D, Colijn C, McLaughlin MM, Abubakar I, Warren RM. Mixed-Strain Mycobacterium tuberculosis Infections and the Implications for Tuberculosis Treatment and Control. Clinical Microbiology Reviews 2012, 25: 708-719. PMID: 23034327, PMCID: PMC3485752, DOI: 10.1128/cmr.00021-12.Peer-Reviewed Original ResearchConceptsMixed infectionsTuberculosis infectionM. tuberculosis infectionTuberculosis control strategiesMycobacterium tuberculosis infectionTreatment of patientsMultiple distinct strainsTuberculosis treatmentInfectionMycobacterium tuberculosisEpidemiological importanceDistinct strainsTreatmentNumerous studiesPatientsTuberculosisDiagnosisHighlight challengesIndividuals
2011
Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy
Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy. PLOS ONE 2011, 6: e18327. PMID: 21479171, PMCID: PMC3068161, DOI: 10.1371/journal.pone.0018327.Peer-Reviewed Original ResearchConceptsMultiple drug resistanceDrug resistanceInitial treatment regimensTB control programsAnti-TB drugsDrug-resistant formsEmergence of resistanceFunctional monotherapyTreatment regimensCombination therapyTB strainsTuberculosis treatmentTherapy rangeM. tbTB bacilliMultidrug resistanceM. tuberculosisDifferent antibioticsTherapyTuberculosisInfected hostControl programsResistant formsTBMonotherapy
2010
The Prevalence and Drug Sensitivity of Tuberculosis among Patients Dying in Hospital in KwaZulu-Natal, South Africa: A Postmortem Study
Cohen T, Murray M, Wallengren K, Alvarez GG, Samuel EY, Wilson D. The Prevalence and Drug Sensitivity of Tuberculosis among Patients Dying in Hospital in KwaZulu-Natal, South Africa: A Postmortem Study. PLOS Medicine 2010, 7: e1000296. PMID: 20582324, PMCID: PMC2889914, DOI: 10.1371/journal.pmed.1000296.Peer-Reviewed Original ResearchConceptsTime of deathTuberculosis treatmentLimited autopsiesM. tuberculosisMultidrug-resistant bacilliCulture-positive tuberculosisInitiation of treatmentMultidrug-resistant tuberculosisHIV-positive individualsMajority of decedentsRespiratory tract secretionsHigh HIV prevalenceSecond-line antibioticsNeedle core biopsySingle public hospitalDiagnosis of tuberculosisAcid-fast bacilliCause of deathNew public health approachPublic health approachMagnitude of deathsFatal courseAdult inpatientsStudy cohortHIV prevalenceDevelopment of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment
Shin SS, Keshavjee S, Gelmanova IY, Atwood S, Franke MF, Mishustin SP, Strelis AK, Andreev YG, Pasechnikov AD, Barnashov A, Tonkel TP, Cohen T. Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment. American Journal Of Respiratory And Critical Care Medicine 2010, 182: 426-432. PMID: 20413630, PMCID: PMC2921603, DOI: 10.1164/rccm.200911-1768oc.Peer-Reviewed Original ResearchConceptsMDR-TB treatmentXDR-TBDrug-resistant tuberculosisMultidrug-resistant (MDR) TBMDR-TB treatment programmeExtensively Drug-Resistant TuberculosisMultidrug-resistant tuberculosis treatmentCox proportional hazards modelDevelopment of XDRMDR-TB therapyTB treatment servicesAmplification of resistanceProportional hazards modelThreefold increaseMDR-TBCavitary lesionsConsecutive patientsAppropriate therapyClinical outcomesTreatment adherenceTuberculosis treatmentInjectable antibioticsTimely initiationPrescribed drugsRetrospective analysis